MYELOMA
Clinical trials for MYELOMA explained in plain language.
Never miss a new study
Get alerted when new MYELOMA trials appear
Sign up with your email to follow new studies for MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Stem cell transplant vs. drugs: which works better for younger myeloma patients?
Disease control CompletedThis study looked at 700 adults up to age 65 with multiple myeloma to see if high-dose therapy with a stem cell transplant works better than standard drug therapy (lenalidomide, bortezomib, and dexamethasone). The goal was to find out which approach delays the cancer from growing…
Matched conditions: MYELOMA
Phase: PHASE3 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can lenalidomide keep myeloma at bay after transplant?
Disease control CompletedThis phase 3 trial tested whether taking lenalidomide (Revlimid) after an autologous stem cell transplant helps people with myeloma stay in remission longer. Over 600 participants under age 65 who had no signs of progression after transplant were randomly assigned to receive lena…
Matched conditions: MYELOMA
Phase: PHASE3 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug shows promise for Hard-to-Treat blood cancer
Disease control CompletedThis study tested a drug called elranatamab in 39 Chinese patients with multiple myeloma that had stopped responding to at least three prior treatments. The drug works by helping the immune system attack cancer cells. The goal was to see if it could shrink tumors and control the …
Matched conditions: MYELOMA
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Donor stem cell transplant shows promise for myeloma patients under 65
Disease control CompletedThis study tested whether a stem cell transplant from a matched donor could improve outcomes for myeloma patients under 65 who had already responded well to their own stem cell transplant. Thirteen patients received a reduced-intensity conditioning regimen followed by the donor t…
Matched conditions: MYELOMA
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Engineered stem cell therapy takes on Hard-to-Treat myeloma
Disease control CompletedThis early-stage trial tested a new therapy called FT576, made from specially engineered stem cells that become cancer-fighting immune cells. It was given alone or with another drug, daratumumab, to 31 people with multiple myeloma that had returned or stopped responding to prior …
Matched conditions: MYELOMA
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New combo therapy for blood cancers shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug combination (duvelisib plus BMS-986345) in 14 people with blood cancers like lymphoma, myeloma, and leukemia. The main goal was to find a safe dose and check for side effects. Researchers also looked at how well the cancer responded after …
Matched conditions: MYELOMA
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Can removing certain immune cells make stem cell transplants safer for myeloma patients?
Disease control CompletedThis early study tested whether removing a specific type of immune cell (regulatory T cells) is safe in 30 people with multiple myeloma undergoing a stem cell transplant. Participants received standard transplant drugs plus a procedure to deplete these cells. The goal was to see …
Matched conditions: MYELOMA
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising Three-Drug cocktail shows strong results in multiple myeloma
Disease control CompletedThis completed study tested a combination of three drugs—bortezomib, lenalidomide, and dexamethasone (VRD)—in 419 newly diagnosed multiple myeloma patients. Some patients also received a stem cell transplant. The goal was to see how well the treatment worked and how long patients…
Matched conditions: MYELOMA
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Can pressurized oxygen boost stem cell transplants for myeloma?
Disease control CompletedThis early-phase study tested whether repeated hyperbaric oxygen therapy is safe for multiple myeloma patients who are about to receive high-dose chemotherapy and a stem cell transplant. Twenty-nine participants were exposed to 100% oxygen at 2.5 times normal atmospheric pressure…
Matched conditions: MYELOMA
Phase: EARLY_PHASE1 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 26, 2026 16:14 UTC
-
Could a simple immunization shield cancer patients from severe COVID-19?
Prevention CompletedThis phase 3 trial tested whether a biologic called IMM-101 could reduce severe respiratory infections, including COVID-19, in cancer patients at higher risk. 195 participants either received three doses of IMM-101 or were simply observed. The goal was to see if the treatment cou…
Matched conditions: MYELOMA
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Prevention
Last updated Jun 27, 2026 08:07 UTC
-
Gentle touch may soothe anxiety for isolated blood cancer patients
Symptom relief CompletedThis study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …
Matched conditions: MYELOMA
Phase: NA • Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Free blood transfusions help blood cancer patients choose hospice
Symptom relief CompletedThis study looked at whether providing free blood transfusions to blood cancer patients would encourage them to enroll in hospice care earlier. Many patients delay hospice because they need transfusions for symptom relief, but hospices often cannot afford to provide them. The stu…
Matched conditions: MYELOMA
Phase: NA • Sponsor: Adam Olszewski • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Exercise before CAR T-Cell therapy: a step in the right direction?
Knowledge-focused CompletedThis study looked at whether an exercise program is practical for people aged 65 and older with blood cancers like lymphoma, leukemia, or myeloma who are about to receive CAR T-cell therapy. The program included remote exercise sessions and was tested with 20 participants to see …
Matched conditions: MYELOMA
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Needle-Free myeloma monitoring: blood test and MRI show promise
Knowledge-focused CompletedThis study explored whether a simple blood test (liquid biopsy) and a whole-body MRI can detect leftover cancer cells in people with multiple myeloma, potentially replacing the need for a bone marrow biopsy. Researchers enrolled 36 adults with newly diagnosed or previously treate…
Matched conditions: MYELOMA
Sponsor: Rajshekhar Chakraborty, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Do vaccines work as well in people with weak immune systems? new study investigates
Knowledge-focused CompletedThis study looked at how well the Pfizer COVID-19 vaccine triggers an immune response in 196 adults with weakened immune systems (due to conditions like kidney transplant, cancer, or HIV) compared to healthy adults. Researchers measured antibody levels and their ability to neutra…
Matched conditions: MYELOMA
Phase: PHASE4 • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC